It's the milestone, CUPID

With the clock ticking on a make-or-break data event this month for Celladon Corp. (NASDAQ:CLDN), investors have sent the stock to its lowest point of the year. The gene therapy company's stock, which was as high as $27.26 on March 19, shed $2.77 (17%) to $13.59 on Thursday and ended the week down $2.84 (17%) at $13.68.

Celladon has said since the start of 2014 that it expects to report data this month from the Phase IIb CUPID 2 trial of Mydicar gene therapy to treat heart failure. ...